Medical education company Fission Communications has created a new oncology division for clients developing new therapies to cure cancer, the company announced this week.
“We were responding to a specific need of our current client base,” said Mario Nacinovich Jr., senior vice president, business development, editorial and strategic planning.
The new division, named Fission Oncology, will work with pharma companies to keep health care providers informed and educated on the newest tools in the treatment of
cancer, he said.
Fission Communications has also added Peter Mirabile as its medical director.
In his new role, Mirabile will provide medical guidance for Fission accounts, a company statement said.
Prior to joining Fission, Mirabile participated in clinical clerkships in the
U.K. and was a former consultant to law firm Chadbourne & Parke, litigation product liability tobacco cases and domestic narcotic pharmaceutical defense strategies.